Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP713
- Development stage
- Preclinical
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
DWP713 is an experimental drug candidate developed by Daewoong Pharmaceutical Co. LTD., currently in the preclinical stage of development for skin tissue regeneration. As part of Daewoong's research into regenerative medicine, DWP713 is designed to facilitate the repair and restoration of damaged skin tissues. While the specific molecular target and mechanism of action have not been publicly disclosed, the candidate likely leverages the company's expertise in growth factors and tissue engineering to promote cellular proliferation and wound healing. DWP713 represents a potential therapeutic option for various dermatological conditions requiring accelerated tissue recovery.
Beyond the preview
Go deeper on DWP713.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP713.